<DOC>
	<DOCNO>NCT01390025</DOCNO>
	<brief_summary>The purpose study compare safety profile healthy volunteer single intravenous administration TCN-032 compare placebo .</brief_summary>
	<brief_title>Safety Study Anti-Influenza Virus Monoclonal Antibody Treat Influenza</brief_title>
	<detailed_description>Influenza highly communicable acute respiratory disease consider one major infectious disease threat human population . Annual vaccination generally effective strain include vaccine . Because frequent emergence divergent variant periodic emergence strain novel hemagglutinin and/or neuraminidase surface protein result global pandemic , availability potent antiviral agent prevention and/or treatment influenza remain urgent clinical public health priority .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy volunteer Normal lab test Prior treatment monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>